Meet Alfa Cytology at the Cancer R&D 2024, Nov 18-20, 2024. We look forward to connecting with you and providing expert solutions for your cancer drug development projects.
Learn More
Leukemia, a type of cancer that affects the blood and bone marrow, is a complex disease with diverse genetic abnormalities. The identification and characterization of pathogenic genes in leukemia have revolutionized our understanding of the disease and paved the way for targeted therapies. Alfa Cytology understands the critical role of comprehensive characterization services in unraveling the pathogenic genes implicated in leukemia. Our state-of-the-art facilities and experienced team of scientists enable us to offer a wide range of services aimed at elucidating the genetic intricacies of leukemia.
Leukemia encompasses a group of hematological malignancies characterized by the uncontrolled proliferation of abnormal white blood cells. While various factors contribute to leukemia development, the discovery of pathogenic genes has shed light on the underlying genetic landscape and provided crucial insights into disease mechanisms. Alterations in genetic material and epigenetic modifications play an important role in the pathogenesis of leukemia, and cytogenetic aberrations have become recognized diagnostic and prognostic markers. Therefore, the study of pathogenic genes of leukemia and the function of leukemia-related genes helps understand the pathogenesis and classification of leukemia.
Fig. 1. Oncogene hierarchy and role of self-renewal in pathogenesis of leukemias. (Jamieson, C.H.M. et al., 2004)
Disease gene identification is the process of identifying mutant genotypes that cause inherited diseases. Mutations in these genes may include single nucleotide substitutions, single nucleotide additions/deletions, whole gene deletions, and other genetic abnormalities. Alfa Cytology provides various disease gene identification services for leukemia, including but not limited to the following.
Based on next-generation sequencing (NGS), we offer comprehensive genomic profiling services, including whole-genome sequencing (WGS), whole-exome sequencing (WES), single nucleotide polymorphism (SNP), and targeted gene panel sequencing. This enables a comprehensive assessment of the mutational landscape in leukemia, facilitating the identification of recurrent gene mutations and their potential clinical implications.
We offer differential expression analyses that quantify changes in gene expression under different conditions or in response to specific stimuli. Leveraging RNA-Seq technology, we can help identify variations in gene expression across different tissues in the context of leukemia. Furthermore, our services include single-cell RNA sequencing, enabling the characterization of gene expression differences between individual cells within complex tissues and providing detailed transcriptome information at a higher resolution. Our results encompass transcript subtypes, gene fusions, splicing variants, gene expression levels, and other pertinent characteristics.
Our comprehensive range of services includes DNA methylation analysis, chromatin accessibility analysis, and DNA-protein binding site analysis. Through these analyses, we provide detailed data on open chromatin regions, DNA methylation patterns, promoter regions, and transcription factor binding sites. This information allows for a comprehensive exploration of gene regulatory mechanisms in leukemia.
Leukemia can be a complex trait controlled by genes at multiple loci, so the QTL analysis we provide can identify molecular markers associated with quantitative changes in specific traits or dynamic outcomes and identify gene networks associated with pathogenesis. QTL analysis can annotate leukemia-related variants, understand the functional effects of variants, and analyze disease-causing and disease-related variants.
To complement pathogenic genes in Leukemia analyses, we offer a range of functional studies and in vitro assays to investigate the impact of pathogenic genes on leukemia biology. This includes cell culture models, gene knockdown or overexpression studies, and analysis of the signaling pathways involved. These experiments enable the assessment of specific gene function and their potential as therapeutic targets.
RNA and DNA Extraction
Library Preparation
Sequencing
Data analysis
Alfa Cytology offers biological technologies for genetic research such as chip and generation sequencing (NGS), as well as advanced sequencing platforms and equipment, which will accelerate your research speed and assist your research on leukemia. Partner with Alfa Cytology and unlock new insights into the genetic landscape of leukemia for improved diagnostics, targeted therapies, and ultimately, better patient outcomes. If you would like to know more about our genetic research services, please contact us.
Reference